Possible cyclosporin-danazol interaction in a patient with aplastic anaemia.
Borrás-Blasco
J
J
Rosique-Robles
J D
JD
Peris-Marti
J
J
Navarro-Ruiz
J
J
Gonzalez-Delgado
M
M
Conesa-Garcia
V
V
D000328:Adult; D000741:Anemia, Aplastic / Q000188:drug therapy*; D016572:Cyclosporine / Q000008:administration & dosage / Q000097:blood / Q000493:pharmacokinetics* / Q000627:therapeutic use; D065607:Cytochrome P-450 Enzyme Inhibitors; D003613:Danazol / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use*; D016903:Drug Monitoring; D004357:Drug Synergism; D004359:Drug Therapy, Combination; D004791:Enzyme Inhibitors / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use; D006801:Humans; D007166:Immunosuppressive Agents / Q000008:administration & dosage / Q000097:blood / Q000493:pharmacokinetics* / Q000627:therapeutic use*; D008658:Inactivation, Metabolic; D008297:Male
D065607:Cytochrome P-450 Enzyme Inhibitors; D004791:Enzyme Inhibitors; D007166:Immunosuppressive Agents; D016572:Cyclosporine; D003613:Danazol